FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC
The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.
Related Articles
A modern view of LGL leukemia
Peripheral T-cell lymphomas are rare and have poorer prognoses than more common B-cell lymphomas. It is therefore appropriate to highlight the current stat
More than £5 million secured for the ICR from Cancer Research UK’s Ra
Cancer Research UK (CRUK) has awarded The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust a substantial £5.14 million through its…
Updates on established therapies in AML – Part 1
In this roundtable discussion, Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, is joined by Tapan Kadia, MD, The University of Texas…
FDA Advises Against Use of BioZorb Markers and BioZorb LP Markers
The FDA has announced that BioZorb Markers and BioZorb LP Markers should no longer be used.
Mechanistic and kinetic insights into transcription factor biology via acute protein depletion
Genetic loss-of-function studies have facilitated the characterization of hematopoietic transcription factors (TFs) in both normal physiology and pathological conditions. The knockout or knockdown of a…
JAK Inhibitors Remain the Gold Standard in Myelofibrosis
Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm.
Navigating Adverse Effects of JAK Inhibitors in Myeloproliferative Neoplasms
Prithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
DE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.
FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Ph+ Chronic-Phase Chronic Myeloid Leukemia
The FDA has granted accelerated approval to asciminib for newly diagnosed, Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.